Arrowhead Pharma (ARWR): Net earnings per share for the last 12 months

Symbol and logo of brand Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals (ARWR) success is based on the test results of therapies for liver and cardiovascular pathologies. The annual net income per share trend visualizes these expectations, where the -5.09 indicator determines the magnitude of the metric. Growth relies on the TRiM platform with a high barrier to entry, while financial stability is supported by licensing royalties from the world's largest pharmaceutical behemoths.

ARWR (Arrowhead Pharmaceuticals) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/15/2026

Summary analytical data breakdowns for Arrowhead Corp (ARWR)

- stock price and consensus target price:
Manufactured products of Arrowhead Pharmaceuticals Inc

This indicator measures the total return of a single stock over a rolling year, allowing for an assessment of the business's actual ability to generate profit after all expenses. By analyzing annual net income per share, an investor can see the impact of the costly cold chain logistics for RNA drugs on the margins of Arrowhead Pharmaceuticals (ARWR), which is critical for understanding the company's financial stability.